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Dengue classically presents as an acute febrile ill-ness lasting ≈5 days and accompanied by head-
ache, musculoskeletal pain, and rash (1). A minority 
of infected persons show development of plasma 
leakage syndrome, intravascular volume loss, or 
major bleeding, which can lead to shock and death 
(2). There are 4 serotypes of dengue (DENV), and 
persons show development of long-lasting immu-
nity to the specific serotype after infection. Cross-
reactive immunity provides short-term protection 
against other serotypes. However, under some cir-
cumstances, previous infection with a different se-
rotype increases the risk for severe disease (3). The 
World Health Organization (WHO) classification 
of dengue focuses on distinguishing between mild 
cases (classic dengue) and persons with or at risk for 
major adverse outcomes or death (severe disease) 
(4–6). Moreover, most literature describing the clini-
cal manifestations of dengue evaluates the health-
care-seeking population whose symptoms are likely 
to be more severe. DENV infections associated with 
milder illness have not been subjected to similar sys-
tematic analysis or characterization.
Although the focus on severe disease is an obvi-
ous priority, there is value to characterizing the sub-
jective illness experience in persons who have milder 
disease. As dengue vaccine development evolves, 
one of the challenges will be to accurately measure 
the effect of vaccination on the severity of illness. 
Measuring the rates of severe disease in vaccine tri-
als is an insensitive approach and addresses only the 
small fraction of cases meeting these criteria, leaving 
open the possibility that vaccinated persons not meet-
ing the criteria for severe disease had a meaningfully 
different disease experience than unvaccinated per-
sons. Behavioral responses and reactions to illness 
depend on the illness experience of a person and will 
determine whether they attend work or school, self-
medicate, seek medical attention, and move around 
their neighborhood, potentially infecting mosquitoes 
at other sites (7). Quantifying these relationships will 
help identify the human factors essential for virus 
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Measuring heterogeneity of dengue illness is necessary 
to define suitable endpoints in dengue vaccine and ther-
apeutic trials and will help clarify behavioral responses 
to illness. To quantify heterogeneity in dengue illness, in-
cluding milder cases, we developed the Dengue Illness 
Perceptions Response (IPR) survey, which captured de-
tailed symptom data, including intensity, duration, and 
character, and change in routine activities caused by 
illness. During 2016–2019, we collected IPR data daily 
during the acute phase of illness for 79 persons with 
a positive reverse transcription PCR result for dengue 
virus RNA. Most participants had mild ambulatory dis-
ease. However, we measured substantial heterogeneity 
in illness experience, symptom duration, and maximum 
reported intensity of individual symptoms. Symptom in-
tensity was a more valuable predicter of major activity 
change during dengue illness than symptom presence 
or absence alone. These data suggest that the IPR mea-
sures clinically useful heterogeneity in dengue illness 
experience and its relation to altered human behavior.
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transmission, guide the design of improved con-
trol strategies, assist policy makers in assessing the 
burden of dengue illness and healthcare needs, and 
guide allocation of resources.
As part of a larger epidemiologic study we devel-
oped the dengue Illness Perceptions Response (IPR) 
survey to gather data to characterize the dengue ill-
ness experience of a person, including the range and 
intensity of symptoms, and to measure the response 
of a person to their illness. We outline the develop-
ment and application of the IPR, and to illustrate its 
potential value, we describe and quantify the hetero-




The study protocol was approved by the Naval Medi-
cal Research Unit No. 6 (NAMRU-6) Institutional 
Review Board (IRB) (protocol #NAMRU6.2014.0028) 
in compliance with all applicable federal regulations 
governing the protection of human subjects. IRB rely-
ing agreements were established between NAMRU-6, 
the University of California Davis, Tulane University, 
Emory University, and the University of California, 
San Diego. The protocol was reviewed and approved 
by the Loreto Regional Health Department, which 
oversees health research in Iquitos.
Field Site
We conducted the study in an established research 
unit in the Amazonian city of Iquitos, Peru (7–9). 
Based in the department of Loreto, Iquitos has a 
population of ≈400,000 and mostly relies on tour-
ism and extractive industries (8,10). More than half 
of the population of Loreto depend on government 
health insurance, which is available for persons liv-
ing in poverty (11). Dengue is endemic to Iquitos, and 
1 serotype typically dominates at any one time; all 4 
DENV serotypes have circulated in Iquitos over the 
past 3 decades (8). The force of infection for DENV 
in Iquitos was calculated to vary from 0 to 0.33 infec-
tions/susceptible person/year during 1999–2010 (12). 
In March 2016, Zika virus was detected in Iquitos, 
and its transmission dominated for ≈1.5 years (13). 
Since 2017, the Asian-American strain of DENV-2 has 
been the dominant circulating serotype (A.C. Morri-
son, unpub. data).
Development of IPR Survey
On the basis of the experience of our team in col-
lecting dengue symptom data and the available 
literature, we developed a focus group guide used 
to facilitate 6 mixed-sex focus groups to assess how 
persons who had recently had dengue illness (or an 
adult family member of a child who was infected) 
described the experience, including the range, du-
ration, and precise location of symptoms; ways to 
describe the severity of the symptoms; and word 
choices related to the symptoms. Focus group par-
ticipants (n = 52) were persons who had laboratory-
confirmed dengue (positive result on DENV reverse 
transcription PCR [RT-PCR]) during the previous 3 
months and who were recruited by ongoing com-
munity or clinic-based febrile illness surveillance. 
Using the range of symptoms and descriptions elic-
ited through the focus groups, the research team 
developed a first version of the IPR, which was re-
viewed by collaborating experts and 3 local clini-
cians experienced in managing dengue to ensure 
its medical relevance. These data informed the IPR 
development, helping to define the symptoms to be 
included and descriptive terms used for symptoms 
and determine how to measure symptom intensity 
(there was almost unanimous support for scales us-
ing facial expressions to grade intensity).
The IPR survey that was implemented collect-
ed data on 36 symptoms; depending on the specific 
symptom, these data included presence, duration, 
intensity, character, frequency and location of symp-
toms (Appendix Table 1, https://wwwnc.cdc.gov/
EID/article/26/9/19-1472-App1.pdf). We learned 
about descriptive terms for various symptoms: mus-
culoskeletal pain was most commonly described as 
“beaten up,” affecting the whole body. Headaches 
were most commonly described as a “generalized 
pressure.” Abdominal pain was most commonly 
described as “cramping” and most frequently lo-
cated in the epigastrium. The survey also asked to 
what extent symptoms had affected daily activities: 
no change, minor change, or major change. The IPR 
was then piloted on 54 persons: 7 children <10 years 
of age, 10 persons 10–20 years of age, and 37 per-
sons >20 years of age. Feedback from this pilot test-
ing was used to guide final modifications of the sur-
vey; data from these persons are not included in the 
main analyses.
Study Design
The study followed a contact-cluster design. Persons 
positive for serum DENV RNA by RT-PCR (index case-
participants) were identified through community- or 
clinic-based febrile illness surveillance (7,14). At the 
time of blood collection, we administered a retrospec-
tive movement survey to the index case-participants 
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to identify locations visited in the previous 15 days. 
As soon as the initial PCR result was available, usually 
the next weekday, persons (contacts) from the home 
of the index case-participants and any residential loca-
tions visited by the index case-participants were then 
invited to provide a blood sample, regardless of the 
presence of symptoms; we tested consenting persons 
for serum DENV RNA by using RT-PCR. The proto-
col enabled requesting follow-up samples from PCR-
negative contacts at intervals of no less than 2 days; 
we tested a median of 2 (interquartile range 2–3) blood 
samples from contacts by using PCR.
Index case-participants and any contacts with 
positive RT-PCR results (15) for DENV RNA were 
invited to respond to a series of surveys relating to 
symptoms (IPR), movements throughout the city, 
health related qualify of life, and illness-related ex-
penditures. The IPR survey was applied daily (where 
possible), starting from the day of the positive RT-
PCR result until there were no reported symptoms 
for 2 days, and then again 30 days later. Inclusion 
criteria for the study were an age >5 years, DENV 
viremia documented by RT-PCR, and willingness to 
provide informed consent or assent for persons 5–17 
years of age.
Data Analysis and Statement
We used CommCare (https://www.dimagi.com), an 
open-source software platform, to develop a digital 
version of the IPR, which we administered by using 
handheld tablets (16). Survey data were uploaded to 
CommCare secure server where it could be reviewed 
by senior project members for discrepancies and cor-
rected if necessary. We forwarded data to a Post-
greSQL database (https://www.postgresql.org) and 
directly accessed this database and analyzed the data 
by using R version 3.5.1 (17). We categorized symp-
toms into the following clinically defined groups: 
constitutional, fever, headache, musculoskeletal, ab-
dominal, cutaneous, respiratory, bleeding, and other 
(Appendix Table 2). The final dataset included the 
first 14 days of illness for each participant, indicating 
for these days symptom intensities from 0 (absence) to 
10 (most intense). The survey solicited the maximum 
symptom intensity experienced between the day of 
collection and either the day the symptom started (in 
the first IPR) or the previous survey (in subsequent 
IPRs). Intensities recorded in the first IPR were as-
signed to the first date that the specific symptom was 
reported and any gaps in intensity data were imputed 
with linear interpolation. For days after the final sur-
vey, intensities and frequencies of symptoms were 
assumed to be 0. From this dataset we calculated the 
duration of illness and of specific symptoms, and the 
proportion of symptoms that were reported on each 
day of illness. Suspected dengue was defined follow-
ing the 2009 WHO guidelines as fever and >2 of the 
following symptoms: headache, retroorbital pain, 
nausea/vomiting, muscle/joint pains, and rash (4).
We performed a correlation analysis of symptom 
intensities, excluding imputed intensity values, by 
using the cor function in the stats package in R with 
use argument as pairwise.complete.observations and 
method argument as spearman to generate a correla-
tion matrix and then plotted a heatmap and dendro-
gram derived from the correlation matrix by using 
the pheatmap function in the pheatmap package (18). 
To compare index and contact cases, we first com-
pared the mean number of reported symptoms by us-
ing a 2-sided Student t-test, and then compared the 
proportions of persons reporting specific symptoms 
by using the Fisher exact test. Because there were 36 
comparisons, we applied a Bonferroni correction to 
the α value.
To explore the relationship between major activ-
ity change and individual symptom intensity, we per-
formed logistic regression by using the glm function 
in the stats package in R, designating major activity 
change (present or absent) as the dependent variable 
and symptom intensity, age, and sex as independent 
variables. To evaluate the benefit of collecting inten-
sity data versus only symptom presence and absence, 
we performed 2 logistic regression models for each 
symptom by using major activity change as the re-
sponse variable and either symptom intensity or bi-
nary symptom presence as the explanatory variable. 
We used the difference in the model Akaike Infor-
mation Criteria (Δ-AIC) as a means to compare the 
2 models, with a positive AIC favoring the use of in-
tensity over presence or absence. All data and R code 
used for this analysis are available (https://github.
com/hammoire/dengue_ipr).
Results
We enrolled 79 persons who completed a total of 429 
IPR surveys (median 5 surveys/person) (Table 1). A 
total of 55 persons were enrolled through febrile ill-
ness surveillance (index case-participants), 42 through 
community-based surveillance, and 13 through clinic-
based surveillance. The remaining 24 persons were en-
rolled through cluster investigations (contact case-par-
ticipants); these case-participants were identified from 
the total of 408 contacts tested (72% of the 567 eligible 
contacts). Index and contact case-participants were 
similar in age and sex. The first survey was completed 
a median of 3 days after the onset of symptoms (range 
Heterogeneity of Dengue Illness in Peru
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–1 to 8 days). A total of 75% of participants completed 
the follow-up survey at a median of 36 days after the 
onset of symptoms (range 21–82 days). Seven (9%) par-
ticipants were hospitalized during the course of their 
acute infection (Table 1).
Frequency and Duration of Symptoms
We summarized the overall frequency (Appendix 
Figure 1) and duration (Appendix Figure 2) of symp-
toms. The frequency of individual symptoms did 
not differ by sex or age group (younger vs. older 
than 18 years of age). All symptoms occurred more 
frequently in index case-participants than in contact 
case-participants, with the exception of vaginal bleed-
ing. These differences were only significant for bad 
taste and chills (p<0.01 with Bonferroni correction) 
(Appendix Table 3).
Participants reported a mean symptom duration 
of 7.37 days. One person (a contact case-participant) 
experienced no symptoms. A total of 5 persons expe-
rienced >1 symptoms between the follow-up visit and 
the last form in the acute phase of illness, including 
nausea (2), malaise (2), headache (1), congestion (1), 
itching (1), and fainting (1).
Timing and Characterization of Symptoms
We report the timing of each of 13 symptoms for 
which duration data were collected (Figure 1). Mal-
aise preceded other symptoms by 1 day in a substan-
tial fraction of cases and was still reported by >30% of 
 
Table 1. Baseline characteristics of participants tested for heterogeneity of dengue illness in community-based prospective study, 
Iquitos, Peru* 
Characteristic Total Index Contact 
No. participants 79 55 24 
No. surveys 429 309 120 
Sex, no. (%)    
 M 38 (48) 27 (49) 11 (46) 
 F 41 (52) 28 (51) 13 (54) 
Median age, y (IQR) 17 (12–27.5) 17 (14–26) 14.5 (9.5–31) 
Day at diagnosis (IQR) 3 (2–4) 4 (3–5) 2 (1–3) 
Serotype, %    
 DENV-2 76 (96) 53 (96) 23 (96) 
 DENV-3 3 (4) 2 (4) 1 (4) 
WHO suspected dengue† (%) 67 (85) 51 (93) 16 (67) 
Warning signs, no. (%) 20 (25) 18 (33) 2 (8) 
Hospitalized, no. (%) 7 (9) 6 (11) 1 (4) 
*DENV, dengue virus; IQR, interquartile range; WHO, World Health Organization. 
†Persons who met the 2009 WHO criteria for suspected dengue (see Methods). 
 
Figure 1. Timing of 13 key dengue symptoms for participants tested for heterogeneity of dengue illness in community-based prospective 
study, Iquitos, Peru. The x-axis represents day of illness and y-axis individual symptoms. Numbers in tiles indicate total number of 
persons with a symptom on that day. A total of 79 persons infected with dengue virus participated in surveys.
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persons at day 7. Fever, headache, and pain (body/
muscle/bone/joint) were most frequently reported 
on days 1–3, whereas abdominal pain was most fre-
quently reported on days 3–5 (Figure 1).
We found substantial heterogeneity in reported 
maximum intensity per symptom by participants. 
We compiled the distribution of the maximum in-
tensity reported by each person during the illness 
period for 12 key symptoms on a 10-point scale (Fig-
ure 2). Symptoms with the highest median values 
for maximum intensity (excluding those that did not 
report the symptom at all) were malaise and fever 
(8), body pain, headache, muscle pain, and weak-
ness (7) (Figure 2).
We report the trajectories of symptom intensity 
over the course of the illness for 6 symptoms (Figure 
3); if the symptom was absent, an intensity of 0 was 
assigned. For the study population as a whole, the in-
tensity of individual symptoms followed a similar tim-
ing as the presence or absence of each symptom. How-
ever, there was substantial variation in the trajectories 
of symptom intensity by participant (Figure 3).
We report correlations between the intensities of 
individual symptoms and the hierarchical clustering 
Figure 2. Histograms of maximum reported symptom intensities for participants tested for heterogeneity of dengue illness in community-
based prospective study, Iquitos, Peru. Persons who did not report symptoms were excluded. Colors in histograms correspond to 
symptom groups defined in Appendix Figure 1 https://wwwnc.cdc.gov/eid/article/26/9/19-1472-App1.pdf. Values for each panel are no. 
(%) of participants who reported the specific symptom at any time during their illness. A) malaise, 78 (98.7); B) weakness, 76 (96.2); C) 
fever, 74 (93.7); D) chills, 65 (82.3); E) headache, 72 (91.1); F) retroorbital pain, 54 (68.4); G) body pain, 61 (77.2); H) bone pain, 51 
(64.6); I) muscle pain, 57 (72.2); J) joint pain, 45 (57.0); K) abdominal pain, 47 (59.5); L) sore throat, 21 (26.6).   
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dendrogram of symptom intensities (Figure 4). Pair-
wise correlations ranged from 0.12 (sore throat vs. 
weakness) to 0.81 (body pain vs. muscle pain). Symp-
tom intensity scores clustered into distinct groups 
(i.e., constitutional [malaise and weakness], fever/
chills, headache/retroorbital pain, and musculoskele-
tal [body, muscle, bone, and joint pains]). Abdominal 
pain and sore throat did not cluster with other symp-
toms in this analysis.
Symptom Intensity and Activity Change
A total of 48 (61%) participants reported a major 
change in their daily activities on >1 days, 25 par-
ticipants (32%) reported a minor change in daily 
activities, and only 6 participants (8%) reported no 
change in daily activities during their illness. On 
the basis of logistic regression models analyzing 
major activity change as a function of individual 
symptom intensities, corrected for age and sex, 
weakness had the strongest association with major 
activity change (odds ratio 1.48, 95% CI 1.36–1.63), 
followed by malaise (odds ratio 1.36, 95% CI 1.25–
1.48) (Table 2).
To assess the added value of measuring symp-
tom intensity versus only symptom absence or 
presence, we compared logistic regression mod-
els that used major activity change as the depen-
dent variable (compared with minor or no activity 
change as reference) and either the presence of a 
symptom or the symptom intensity as the indepen-
dent variable. The difference in the model (Δ-AIC) 
was used to compare the 2 models, in which a posi-
tive Δ-AIC would favor the use of symptom inten-
sity over presence/absence alone. Symptoms with 
the greatest positive Δ-AIC were malaise (Δ-AIC 
42.1), weakness (Δ-AIC 35.8), and fever (Δ-AIC 
20.8) (Table 2). These data indicate that symptom 
intensity is more valuable than symptom presence 
or absence alone as a predictor of major activity 
change during DENV infection.
Discussion
Symptoms reported most frequently by study par-
ticipants were consistent with classical descriptions 
of dengue illness, other cohort studies, and WHO 
guidelines, as well as the key symptoms reported by 
participants in our focus groups (19–22), although 
a large fraction of participants reported less typical 
gastrointestinal or respiratory symptoms. Partici-
pants enrolled as contact case-participants reported 
Figure 3. Symptom intensities (scale 0–10) for 6 symptoms over the first 14 days of illness (0–13) for participants tested for 
heterogeneity of dengue illness in community-based prospective study, Iquitos, Peru. A) Malaise; B) weakness; C) fever; D) headache; 
E) body pain; F) abdominal pain. Box plots indicate trends for the study population as a whole. Dark horizontal lines indicate median, 
upper limit of box indicates 75th percentile, lower limit of box indicates 25th percentile, upper whisker extends to the largest value <1.5 
times the interquartile range; and lower whisker extends to the smallest value >1.5 times the interquartile range. Black dots indicate 
individual scores. Colored lines indicate trajectories for a random sample of 10 individual participants.
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fewer symptoms, similar to the findings in cluster 
investigations performed in Thailand (23). Some 
of these persons might otherwise not have sought 
medical attention. Only 1 (contact case-participant) 
person reported no symptoms. This finding con-
flicts with evidence suggesting that only 12%–25% 
of DENV infections are apparent (24,25). However, 
it is likely that administering the IPR survey encour-
aged reporting of symptoms that would not have 
been recalled in the context of a retrospective ques-
tionnaire, possibly explaining the relatively high 
symptomatic to asymptomatic ratio in our sample. 
We only collected data for persons who had a posi-
tive RT-PCR result (persons with only immunologic 
evidence of seroconversion to DENV were not in-
cluded). This limitation has been associated with a 
higher frequency of symptoms (23).
Although most persons had mild dengue ill-
ness, our data demonstrate a range of intensity 
levels for individual symptoms. The IPR survey 
also enabled us to identify symptom groups with-
in which daily intensities were highly correlated 
Figure 4. Correlations of intensities of individual symptoms (379 surveys, 79 participants) and hierarchical clustering for participants 
tested for heterogeneity of dengue illness in community-based prospective study, Iquitos, Peru. Tile colors indicate strength of 
correlations. The height at which symptoms are linked in the dendrogram indicates how strongly they are related (lower height indicates 
a closer link).
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(r >0.70): constitutional (malaise and weakness), 
fever (fever and chills), headache (headache and 
retroorbital pain), and musculoskeletal pain (body, 
muscle, bone, and joint pain).
Abdominal pain was reported by 59% of partici-
pants, but only 13% reported severe abdominal pain 
(intensity >6). Abdominal pain followed a somewhat 
different time course from and showed substantially 
lower correlation with the symptom groups listed 
above. This finding is consistent with a distinct physi-
ologic mechanism for abdominal pain. It also sup-
ports guidelines classifying severe abdominal pain as 
a warning sign, although few of our participants had 
evidence of plasma leakage or severe bleeding.
Although our study population consisted pri-
marily of persons with mild dengue illness, partici-
pants still reported a substantial impact of illness on 
daily activities. Use of intensity scores for the major 
symptoms substantially improved the assessment of 
the effects of illness on daily activities when com-
pared with use of symptom presence/absence alone. 
Therefore, the ability of the IPR survey to capture 
this aspect of heterogeneity in nonhospitalized per-
sons with dengue could help improve assessment of 
either beneficial or detrimental effects of interven-
tions, as proposed by Thomas et al. (26). Moreover, 
the causes of specific symptoms in dengue remain 
poorly defined (19); instruments such as the IPR sur-
vey could potentially be used to explore these un-
derlying mechanisms.
Recently, a group of experts proposed a data col-
lection tool to capture the overall experience of a per-
son with dengue based on how their symptoms affect 
general wellness and functionality (26). The Dengue 
Illness Index (DII) records the presence or absence of 
symptoms daily. Our IPR survey has similarities to 
the DII, but a major difference is that the IPR solicited 
the assessment of the intensity of key symptoms of a 
participant. Our data suggest that persons are able to 
provide such an assessment and that intensity data 
add information relevant to the overall assessment of 
illness impact.
Thomas et al. (26) proposed a strategy for tabu-
lating the DII to yield a single illness score. We did 
not assign weights a priori for the different symp-
tom intensities. Our data showing high correlations 
within symptom groups suggests that each symptom 
should not be given equal weight. We are exploring 
approaches to express the symptom severity data 
to a single or small number of the most informative 
parameters (e.g., principal component analysis). Re-
gardless of the specific approach used to score den-
gue symptom severity, it will be essential to define the 
relationships of severity score to other external mea-
sures of illness impact. In addition to data on change 
in daily activities, described here, persons also pro-
vided data on movement (14) and on a health-related 
quality of life survey, which we are incorporating into 
future analyses.
Our findings should be interpreted in light of 
several additional limitations. The IPR survey was 
administered to participants by research staff using 
a tablet-based application. Some choices in the de-
sign of the tablet-based survey addressed operation-
al needs or preferences of the research team. These 
considerations created some unanticipated chal-
lenges and required minor modifications to the tool 
during the course of our study. For example, as a re-
sult of delays in receiving RT-PCR results or missed 
follow-up assessments, it was difficult to accurately 
assign a start and end date of some symptoms for 
some persons. Imputation of missing data introduc-
es error into our dataset that is difficult to quantify. 
Our sample size is relatively small and homogenous 
in host and viral populations. Our study was focused 
on evaluation of persons with acute DENV infection 
and did not include participants with nondengue fe-
brile illnesses for comparison. Persons who partici-
pated in the focus groups or the main study are not 
representative of the overall population of Iquitos 
(e.g., greater time availability or willingness to en-
gage with medical personnel). That said, the instru-
ment development process, which engaged partici-
pants recently given a diagnosis of DENV infection 
and clinical experts who reviewed the literature, re-
sulted in a tool that assessed a wide range of symp-
toms and potential behavioral responses, which we 
believe could be applied in other settings, although 
 
Table 2. Effect of symptom intensity on reporting of major activity 
change for participants tested for heterogeneity of dengue illness 
in community-based prospective study, Iquitos, Peru 
Symptom Odds ratio (95% CI)* Δ-AIC† 
Malaise 1.36 (1.25–1.48) 42.1 
Weakness 1.48 (1.36–1.63) 35.8 
Fever 1.28 (1.19–1.38) 20.8 
Abdominal 1.34 (1.22–1.48) 9.9 
Body pain 1.32 (1.22–1.43) 9.1 
Headache 1.27 (1.17–1.37) 9.0 
Chills 1.31 (1.21–1.43) 3.3 
Muscle pain 1.25 (1.15–1.35) 2.7 
Joint pain 1.23 (1.13–1.34) −0.0 
Retroorbital pain 1.11 (1.03–1.2) −0.1 
Sore throat 1.02 (0.87–1.18) −0.5 
Bone pain 1.24 (1.15–1.36) −1.4 
*Shown is the increase in odds of reporting a major activity change when 
symptom intensity is increased by 1 point for each of the 12 symptoms.  
†Δ-AIC, difference in Akaike Information Criteria between models by using 
binary symptom presence versus symptom intensity (0–10) as a predictor 
of major activity change. A positive Δ-AIC favors the use of intensity over 
presence of symptom alone. 
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piloting the tool before use elsewhere is advisable. 
Febrile illness surveillance was limited to selected 
neighborhoods, and contacts were identified on the 
basis of social proximity. Given the long-standing 
interactions of the research team with the local pop-
ulation and the demographics of study participants, 
we do not expect these considerations to have intro-
duced major bias in our results.
Our data support the feasibility and rationale 
of efforts to quantify dengue illness in future nat-
ural history and intervention studies. Our experi-
ence should be useful to guide development of 
reliable and validated tools for this purpose. We 
anticipate that the IPR survey could be adapted to 
other formats, including self-administration by re-
search subjects, and to other languages, but these 
efforts would require modifications and further 
validation. Further studies are needed to test our 
results across other populations, to assign appro-
priate weights to individual symptom scores, and 
to correlate with other biologic and epidemiologic 
measures of disease impact.
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